Vorasidenib,Atezolizumab,Cabozantinib
servier,Roche
['rectal', 'breast']
kicking off #asco23: phase 3 studies in breast, rectal, kidney and brain cancer headline research at asco annual meeting. follow our twitter for full conference coverage.
read more 
Your official source for @DanaFarber Cancer Institute news | Research, science, and innovation | Media requests: media@dfci.harvard.edu or 617-632-4090